| Dr Dorsett David Smith, MD | |
|
5921 E Ocupado Dr, Cave Creek, AZ 85331-1549 | |
| (480) 415-7094 | |
| (425) 259-5171 |
| Full Name | Dr Dorsett David Smith |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 5921 E Ocupado Dr, Cave Creek, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760894885 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 35067 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dorsett David Smith, MD 5921 E Ocupado Dr, Cave Creek, AZ 85331-1549 Ph: (480) 415-7094 | Dr Dorsett David Smith, MD 5921 E Ocupado Dr, Cave Creek, AZ 85331-1549 Ph: (480) 415-7094 |
News Archive
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis- and Avastin-, the two medications most widely used to treat the "wet" form of AMD.
Research funded by the Dengue Vaccine Initiative (DVI) involving an economic analysis of producing a tetravalent dengue vaccine shows that the cost could be as low as $0.20 per dose with an annual production level of 60 million doses packaged in ten-dose vials. The study used data on a vaccine developed by US NIH and the facilities of the Instituto Butantan in Sao Paulo, Brazil.
Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.
Research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, has identified an enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target to treat or prevent Alzheimer's disease.
The composition of bacteria in the gastrointestinal tract may hold clues to help predict which cancer patients are most apt to benefit from the personalized cellular therapies that have shown unprecedented promise in the fight against hard-to-treat cancers, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
› Verified 4 days ago
Dr. Oladapo O Odumosu, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 28248 N Tatum Blvd, Bldg B-1 #605, Cave Creek, AZ 85331 Phone: 602-996-5595 Fax: 602-996-5610 | |
Dr. Rebecca Ann Cook, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 30633 N 46th Pl, Cave Creek, AZ 85331 Phone: 623-518-0719 Fax: 480-427-4988 | |
Dr. Laura Arlene Knecht, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 6725 E Dove Valley Rd, Cave Creek, AZ 85331 Phone: 602-524-3758 Fax: 774-209-4329 | |
Michael Patrick Newcomb, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 29455 N Cave Creek Rd, Suite 118-605, Cave Creek, AZ 85331 Phone: 602-996-5595 Fax: 602-996-5610 | |
Nha T Lien, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 28248 N Tatum Blvd, Bldg B-1 #605, Cave Creek, AZ 85331 Phone: 602-996-5595 Fax: 602-996-5610 |